Wall Street analysts expect that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will post sales of $708.34 million for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Endo International’s earnings, with the highest sales estimate coming in at $728.30 million and the lowest estimate coming in at $699.80 million. Endo International posted sales of $745.47 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 5%. The firm is expected to report its next earnings report on Thursday, November 14th.
On average, analysts expect that Endo International will report full year sales of $2.86 billion for the current year, with estimates ranging from $2.82 billion to $2.89 billion. For the next fiscal year, analysts forecast that the company will report sales of $2.86 billion, with estimates ranging from $2.64 billion to $2.98 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $699.71 million during the quarter, compared to the consensus estimate of $694.60 million. Endo International had a negative return on equity of 129.30% and a negative net margin of 19.98%. Endo International’s revenue for the quarter was down 2.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.76 earnings per share.
In related news, Director Roger H. Kimmel sold 34,951 shares of the stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $3.93, for a total value of $137,357.43. Following the completion of the transaction, the director now directly owns 148,309 shares in the company, valued at approximately $582,854.37. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.50% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of ENDP. Paloma Partners Management Co bought a new position in shares of Endo International in the 2nd quarter worth about $98,000. Meeder Asset Management Inc. grew its position in Endo International by 47.1% during the 2nd quarter. Meeder Asset Management Inc. now owns 37,887 shares of the company’s stock valued at $156,000 after purchasing an additional 12,127 shares during the last quarter. Factorial Partners LLC purchased a new stake in Endo International during the 1st quarter valued at about $193,000. Commonwealth Bank of Australia grew its position in Endo International by 41.6% during the 2nd quarter. Commonwealth Bank of Australia now owns 66,400 shares of the company’s stock valued at $273,000 after purchasing an additional 19,500 shares during the last quarter. Finally, Hunter Associates Investment Management LLC grew its position in Endo International by 37.4% during the 2nd quarter. Hunter Associates Investment Management LLC now owns 94,075 shares of the company’s stock valued at $388,000 after purchasing an additional 25,625 shares during the last quarter. Institutional investors own 95.80% of the company’s stock.
NASDAQ ENDP traded down $0.04 on Tuesday, hitting $3.92. 167,274 shares of the stock traded hands, compared to its average volume of 9,744,917. The stock has a 50-day moving average of $2.77 and a 200 day moving average of $5.64. Endo International has a twelve month low of $1.97 and a twelve month high of $18.50. The company has a market capitalization of $929.40 million, a P/E ratio of 1.36 and a beta of 1.23.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
See Also: Monthly Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.